Abstracts tagged "Cardiovascular"

Abstract Number: 2106 • ACR Convergence 2023
Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls
Stephen Oakley¹, Samantha Stott¹, Kerri Gill¹, Chan Virgil¹, Lyanne Weston² and Theo de Malmanche¹, ¹John Hunter Hospital, New Lambton, Australia, ²Australian Red Cross Blood Service, Alexandria, Australia
Background/Purpose: The risk of developing ACPA+RA, predictors of severity and causes of excess cardiovascular disease (CVD) are incompletely understood. We have observed that RA patients…
Abstract Number: 2428 • ACR Convergence 2023
Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Natalie McCormick¹, Kehuan Lin², Chio Yokose³, Na Lu⁴, Yuqing Zhang¹ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…
Abstract Number: 0391 • ACR Convergence 2023
Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapää-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹⁰, Virginia Pascual Ramos¹¹, Irazú Contreras Yañez¹², Iris Colunga¹³, Dionicio A. Galarza-Delgado¹³, José Ramón Azpiri-López¹³, Silvia Rolefstad¹⁴, Anne Grete Semb¹⁵, Durga P Misra¹⁶, Ellen Margrethe Hauge¹⁷ and GEORGE KITAS¹⁸, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁵Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷Aarhus University Hospital, Aarhus, Denmark, ¹⁸The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Chronic inflammation contributes to enhanced cardiovascular risk in rheumatoid arthritis (RA). Biologic disease modifying antirheumatic drugs (bDMARDs) control inflammation in many conventional synthetic DMARD…
Abstract Number: 0580 • ACR Convergence 2023
Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus
Gayathri MS, Aishwarya Gopal, Molly Mary Thabah, Christina Mariaselvam, jaiveer Singh and Chengappa Kavadichanda, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Cardiovascular disease (CVD) is a major cause of mortality in systemic lupus erythematosus (SLE). Role of conventional risk scores which predict cardiovascular events, to…
Abstract Number: 0898 • ACR Convergence 2023
The Role of the Endothelin System in the Development of TLR7-accelerated Lupus-Associated Cardiac Dysfunction
Kennedy Hawkins, Marice McCrorey, C. Alex Colvert, Kristine DeLeon-Pennell, Melissa Cunningham and Justin Van Beusecum, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by autoantibody formation and immune complex deposition in target organs. While it is known that…
Abstract Number: 1283 • ACR Convergence 2023
Atherogenic Index of Plasma Identifies Patients with Rheumatoid Arthritis and Increased Carotid Intima-Media Thickness
Dionicio A. Galarza-Delgado¹, Iris Colunga¹, José Ramón Azpiri-López¹, Valeria Gonzalez-Gonzalez², Victor Beltran³, Angel Arias Peralta⁴, Jesus Alberto Cardenas-De la Garza⁵ and Rosa Arvizu-Rivera⁶, ¹Hospital Universitario UANL, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: The atherogenic index of plasma (AIP) is a novel marker to identify cardiovascular disease. Recently, AIP was reported to be related to long-term cardiovascular…
Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Yasaman Ahmadzadeh², Danieli Andrade³, leslie skeith⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Denis WAHL¹⁴, Maria Gerosa¹⁵, Guilherme De Jesús¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Laura Andreoli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁷, Guillermo Pons-Estel²⁸, Rohan Willis²⁹, Ali Duarte-Garcia³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Doruk Erkan¹ and On Behalf Of APS ACTION³³, ¹Hospital for Special Surgery, New York, NY, ²Roger Williams Medical Center, Providence, RI, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Milan, Milano, Italy, ¹⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷University of Michigan, Ann Arbor, MI, ²⁸CREAR, Rosario, Argentina, ²⁹University of Texas Medical Branch, Galveston, TX, ³⁰Mayo Clinic, Rochester, MN, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³on behalf of APS ACTION, New York, NY
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
Abstract Number: 2118 • ACR Convergence 2023
New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry
Robert Spandorfer¹, Kevin Kane², George Reed², Dimitrios Pappas², Joel Kremer², Jeffrey Curtis³ and Iris Navarro-Millán⁴, ¹Hospital for Special Surgery, Brooklyn, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
Abstract Number: 2430 • ACR Convergence 2023
Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², H. Myra Kim¹, Bryant England³, Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Punyasha Roul³, Ted R Mikuls⁷, Shirley Cohen-Mekelburg¹, Daniel Clauw⁸, Wyndy Wiitala², Rodney Hayward¹, Jeremy Sussman¹ and Akbar Waljee⁹, ¹VA Ann Arbor; University of Michigan, Ann Arbor, MI, ²VA Ann Arbor, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁹VA Ann Arbor, University of Michigan, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events…
Abstract Number: 0419 • ACR Convergence 2023
No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors
Romy Hansildaar¹, Reinder Raadsen¹, Maaike Heslinga² and Michael Nurmohamed², ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-fold higher risk of venous thromboembolism (VTE) compared with the general population. The immune system and hemostatic…
Abstract Number: 0634 • ACR Convergence 2023
Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study
Raychel Barallon¹, Gene-Siew Ngian¹, Diane Apostolopoulos¹, Dylan Hansen², Kathleen Morrisroe³, Wendy Stevens⁴, Susanna Proudman⁵, Mandana Nikpour⁶ and Joanne Sahhar¹, ¹Monash Health and Monash University, Clayton, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ⁴Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁵Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ⁶The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Anaemia in systemic sclerosis (SSc) is under-studied and under-characterised. Its prevalence amongst SSc patients is not well described, nor are its effects on outcomes…
Abstract Number: 0901 • ACR Convergence 2023
Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus
Jaya Krishnan¹, Néstor de la Visitación¹, Jonathan Williams¹, Leslie Crofford² and David Patrick³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR, ³Department of Veterans Affairs, Nashville, TN
Background/Purpose: Atherosclerosis and vascular inflammation are a cause of morbidity and mortality in systemic lupus erythematosus (SLE). Vascular NETosis is a driver of atherosclerosis and…
Abstract Number: 1291 • ACR Convergence 2023
Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Toshitaka Hirano¹, Naonobu Sugiyama², Masato Hoshi¹, Joo-Young Jo³, Kichul Shin⁴ and Kunihiro Yamaoka⁵, ¹Pfizer Japan Inc, Tokyo, Japan, ²Pfizer Japan Inc, Japan, Japan, ³Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…
Abstract Number: 1627 • ACR Convergence 2023
Methotrexate Use Associates with Ischemic Cardiovascular Risk Reduction in Males but Not Females with Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapää-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹⁰, Virginia Pascual Ramos¹¹, Irazú Contreras Yañez¹², Iris Colunga¹³, Dionicio A. Galarza-Delgado¹³, José Ramón Azpiri-López¹³, Silvia Rolefstad¹⁴, Anne Grete Semb¹⁵, Durga P Misra¹⁶, GEORGE KITAS¹⁷ and Ellen Margrethe Hauge¹⁸, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁵Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ¹⁸Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) experience higher cardiovascular risk compared to non-inflammatory disease controls. Methotrexate (MTX) may decrease cardiovascular risk in patients with RA.…
Abstract Number: 2119 • ACR Convergence 2023
Serum Alarmin Concentrations and Risk of Incident Major Adverse Cardiovascular Events and Heart Failure in a Multicenter, Prospective Rheumatoid Arthritis Cohort
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Michael Duryee¹, Carlos Hunter¹, Joshua Baker², Brian Sauer³, Grant Cannon⁴, Amy Joseph⁵, K Wysham⁶, Aleksander Lenert⁷, Geoffrey Thiele¹, Jill Poole¹, Ted R Mikuls⁸ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Washington University / St. Louis VA, St. Louis, MO, ⁶VA Puget Sound/University of Washington, Seattle, WA, ⁷University of Iowa, Iowa City, IA, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Alarmins are endogenous cytokines released following cellular damage and physiologic stress to promote homeostasis through tissue inflammation, remodeling, and fibrosis. Alarmins may facilitate maladaptive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].